Based on the information available, there is no definitive answer to how many nivolumab treatments patients usually receive. The appropriate duration and frequency of nivolumab treatment can vary depending on several factors, including the patient's health condition, the type and stage of cancer, and the patient's response to the treatment.

Nivolumab is a type of immunotherapy drug that works by stimulating the body's immune system to fight cancer cells. It is often used to treat various types of cancer, such as melanoma, lung cancer, and kidney cancer. The dosage and schedule of nivolumab treatment are typically determined by the patient's healthcare provider, based on the patient's individual needs and circumstances.

According to DrugPatentWatch.com, nivolumab is approved for intravenous infusion at a dose of 240 mg every two weeks or 480 mg every four weeks. However, the number of treatments a patient receives can vary widely, and some patients may continue to receive nivolumab therapy for several months or even years, depending on their response to the treatment.

In summary, the number of nivolumab treatments that patients usually receive cannot be determined without considering the individual patient's circumstances. Healthcare providers determine the appropriate dosage and schedule of nivolumab treatment based on each patient's needs.

Sources:

* DrugPatentWatch.com. (n.d.). Nivolumab. Retrieved from <https://www.drugpatentwatch.com/drugs/nivolumab>